Overall verdict
Neutral
5.5/10
1-year performance
-25.14%
Score breakdown
Down 25.1% over 1 year, 18% of the 52-week range.
11 analysts.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Carole Ben-Maimon
Founded
—
Employees
71
Revenue / employee
0 USD
Next earnings
March 19, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC1.68%
- FMR LLC1.05%
- Bank of New York Mellon Corp0.14%
- Rest of the register97.13%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
6.42 USD
52-week low
1.92 USD
1-year performance
-25.14%
Declining
Year-to-date performance
-27.93%
Declining
Drawdown
-57.79%
Major drawdown
Position in the 52-week range
18% of range
ROIC -135.7%, ROE -139.6%.
Net margin
—
Sector -207.84%|S&P 13.40%
Gross margin
—
Return on equity (ROE)
-139.63%
Negative
Sector -57.81%|S&P 17.06%
Return on invested capital (ROIC)
-135.66%
Negative
Free cash flow margin (FCF)
—
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Market cap
282M USD
Financial strength
5.8/10Cash covers 3153.1% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-118.79%
Net cash
Cash
156M USD
Cash / market cap
55.51%
Very solid
Cash / total debt
3153.09%
Net cash
Interest coverage
-114.2x
Stretched
Net debt
-151M USD
Equity
127M USD
Closed daily candles, 2 years
Last close on November 10, 2026: 2.69 USD
- MM202.38
- MM503.00
- MM2003.78
- RSI 1452.0
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-3.05%
200-day average slope, 3 months
-3.23%
50-day average slope, 1 month
-19.94%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
7.04 % per day
Volatility change
+55.75%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.35 (10) | -1.37 (8) | 0 (11) | -143 (3) | -139 (9) |
| 2027 | -1.18 (10) | -1.06 (8) | 42 (11) | -137 (3) | -155 (8) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.5 | N/A | 282M USD | Not meaningful (loss) | — | — | -135.7 % | — | -55.4 % | -25.1 % | ||
| 2 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 5 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 6 | SABS | 2.9 | 0.9 | 280M USD | Not meaningful (loss) | -6088.9 % | -100.0 % | -34.5 % | 1.2x | -21.0 % | -1.3 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -43.3 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 298M USD | Not meaningful (loss) | — | — | -25.6 % | 8.3x | -1.8 % | 900.5 % |
